Screening for transient biological interactions as applied to albumin ligands: a new concept for drug discovery.
The notion that many biological interactions are based on transient binding (dissociation constants (K(d)) in the range of 10-0.01 mM) is familiar, yet the implications for biological sciences have been realized only recently. An important area of biological sciences is drug design, where the traditional "lock and key" view of binding has prevailed and drug candidates are usually selected on their merits as being tight binders. However, the rationale that transient interactions are of importance for drug discovery is slowly gaining acceptance. These interactions may relate not only to the desired target interaction but also to unwanted interactions creating, for example, toxicity problems. Here we demonstrate, in a high-throughput screening format, affinity selection of weak binders to a model target of albumin by zonal retardation chromatography. It is perceived that this approach can define the "transient drug" as a complement to current drug discovery procedures.
Ohlson
Sten
S
Department of Chemistry and Biomedical Sciences, University of Kalmar, SE-391 82 Kalmar, Sweden. sten.ohlson@hik.se
Shoravi
Siamak
S
Fex
Tomas
T
Isaksson
Roland
R
D000418:Albumins / Q000737:chemistry* / Q000378:metabolism*; D001665:Binding Sites; D002846:Chromatography, Affinity; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004347:Drug Interactions; D008024:Ligands; D011485:Protein Binding; D011506:Proteins / Q000737:chemistry / Q000378:metabolism*; D013056:Spectrophotometry, Ultraviolet
D000418:Albumins; D008024:Ligands; D011506:Proteins